Teva Pharmaceuticals
U.S. Headquarters
1090 Horsham Road
North Wales
Pennsylvania
19454
United States
Tel: 888-838-2872
Website: https://www.tevausa.com/
1779 articles about Teva Pharmaceuticals
-
Teva Pharmaceuticals and Alvotech got the FDA’s greenlight for their biosimilar to Johnson & Johnson’s blockbuster Stelara, which will launch in the U.S. in February 2025.
-
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
4/16/2024
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced final results from the HD cohort of the Phase 4 START study, demonstrating positive real-world effectiveness, safety, adherence and satisfaction with the 4-week Titration Kit for AUSTEDO.
-
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
4/16/2024
Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that the U.S. Food and Drug Administration has approved SELARSDI injection for subcutaneous use, as a biosimilar to Stelara®, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older.
-
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
4/11/2024
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a Phase 3 study evaluating the efficacy and safety of AJOVY for the prevention of migraine in adult Chinese patients.
-
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
4/9/2024
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2024 financial results on Wednesday, May 8, 2024, at 7:00 a.m. ET.
-
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
4/6/2024
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced the presentation of eight studies from its LAI schizophrenia research program, including data evaluating UZEDY, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia in adults.
-
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
4/3/2024
UroGen Pharma Ltd. today announced that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries, Ltd., alleging infringement of U.S. Patent Numbers 9,040,074 (“the ’074 patent”) and 9,950,069.
-
A federal appeals court Monday backed Teva and Viatris’ challenge to a lower court ruling, finding that the companies can again make their case against Johnson & Johnson’s patent covering its schizophrenia drug Invega Sustenna.
-
Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement
4/1/2024
Teva Pharmaceutical Industries Ltd. and Launch Therapeutics, Inc., announced a clinical collaboration agreement to further accelerate the clinical research program of Teva’s ICS-SABA.
-
Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China
2/26/2024
Teva Pharmaceutical Investments Singapore Pte Ltd, a subsidiary of Teva Pharmaceutical Industries Ltd. and Jiangsu Nhwa Pharmaceutical Co., Ltd announced it formed a partnership for the marketing and distribution of Teva’s AUSTEDO for the treatment of neurodegenerative and movement disorders - chorea associated with Huntington’s disease and tardive dyskinesia in adults.
-
On Friday, Alvotech and Teva Pharmaceuticals finally secured the FDA’s greenlight for their Humira biosimilar Simlandi, which now has the regulator’s interchangeability designation.
-
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
2/24/2024
Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that the U.S. Food and Drug Administration has approved SIMLANDI injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis.
-
Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting
2/20/2024
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. today announced positive safety, tolerability, and pharmacokinetic data for its anti-TL1A (TEV-’574) asset, a potentially best-in-class human IgG1 monoclonal antibody that targets the tumor necrosis factor (TNF)-like ligand 1A (TL1A) and is designed to offer both anti-inflammatory and anti-fibrotic effects.1-3
-
Teva Reports Growth in Fourth Quarter and Full Year 2023
1/31/2024
Teva Pharmaceutical Industries Ltd. reported results for the year and the quarter ended December 31, 2023.
-
MedinCell’s partner Teva Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK / Olanzapine Long-Acting Injectable (LAI)
1/9/2024
Teva Pharmaceutical Industries Ltd. announced the successful completion of the enrollment in the EU and US of the anticipated 640 participants of the ongoing Phase 3 clinical trial of mdc-TJK (TEV-44749) at the J.P. Morgan Healthcare Conference.
-
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance at 8 a.m. ET on January 31, 2024
1/2/2024
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2023 financial results, as well as on its financial guidance for 2024, on Wednesday, January 31, 2024, at 7:00 a.m. ET.
-
Teva to Present at the 42nd Annual J.P. Morgan Healthcare Conference
12/28/2023
Teva Pharmaceutical Industries Ltd. announced that Richard Francis, Teva's President and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024.
-
New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity
12/6/2023
Teva Pharmaceutical Industries Ltd. announces that a post hoc analysis4 of two phase 3 clinical studies presented at the European Headache Congress has shown the effectiveness of the migraine prevention treatment AJOVY® in reducing migraine attacks in patients with migraine and co-morbid obesity.
-
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
11/30/2023
Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today closing of its collaboration deal to co-develop and co-commercialize asset TEV ‘574 with Sanofi (EURONEXT: SAN and NASDAQ: SNY).
-
Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.
11/17/2023
Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the approval of a generic version of Forteo®1, in the United States. Market availability of the product in the U.S. is expected in the coming weeks.